Associated Papers
Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.
Matthew AN et al.
Structure (london, England : 1993), 2018
Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N et al.
Interdisciplinary Sciences, Computational Life Sciences, 2018
Protease Inhibitors Drug Resistance Mutations in Turkish Patients with Chronic Hepatitis C.
Sargin Altunok E et al.
International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases, 2016
Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy.
Abdel-Hameed EA et al.
Viral Immunology, 2016
Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group.
Bai F et al.
International Journal of Molecular Medicine, 2014
High-throughput screening (HTS) and hit validation to identify small molecule inhibitors with activity against NS3/4A proteases from multiple hepatitis C virus genotypes.
Lee H et al.
Plos One, 2013
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.
Susser S et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 2011
Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Zhou Y et al.
Antimicrobial Agents and Chemotherapy, 2008
Select a paper to view details